Australian biotech market watch 11/11/09
Wednesday, 11 November, 2009
Amongst the biggest winners today is Biota Holdings (ASX:BTA), up 7c to $2.78, after seeing fluctuating prices over the last couple of weeks.
Pharma company, ChemGenex (ASX:CXS), gained 3c to 91c, on the back of news of the FDA granding Priority Review status to its anti-leukaemia drug, Omapro, earlier this week.
CSL (ASX:CSL) is also up, lifting 1.5% to $32.30, recovering the losses it experienced throughout October.
Falls were experienced by pSividia (ASX:PVA), which dropped 10% to $3.23 in moderate trading, and Patrys (ASX:PAB), which this morning announced the awarding of a grant to researchers collaborating on one of its anti-cancer treatments, fell 1c to 16c.
Blackmores (ASX:BKL) dropped 40c to $20.80, and ResMed (ASX:RMD), lost 5c to $5.27. Cochlear (ASX:COH) also fell by 51c to $62, down by 0.82%.
The All Ordinaries has experienced its fourth consecutive day of gains, up 19.5 points to 4,763.5 as of 4pm this afternoon, mainly on the back of property trusts.
Anti-inflammatory agent could decrease septic shock mortality
Researchers have discovered a naturally occurring blood protein — a type of...
Less penicillin needed to treat Strep A infection than we thought
It's never been known exactly how much penicillin prevents sore throats — the most...
Stress disrupts emotion control in mental illness
Acute stress may impair key brain functions involved in managing emotions — particularly in...
